Attached files
| file | filename |
|---|---|
| S-1 - S-1 - Aralez Pharmaceuticals Inc. | a2226999zs-1.htm |
| EX-10.2 - EX-10.2 - Aralez Pharmaceuticals Inc. | a2226999zex-10_2.htm |
| EX-10.1 - EX-10.1 - Aralez Pharmaceuticals Inc. | a2226999zex-10_1.htm |
| EX-10.3 - EX-10.3 - Aralez Pharmaceuticals Inc. | a2226999zex-10_3.htm |
| EX-23.3 - EX-23.3 - Aralez Pharmaceuticals Inc. | a2226999zex-23_3.htm |
| EX-23.2 - EX-23.2 - Aralez Pharmaceuticals Inc. | a2226999zex-23_2.htm |
QuickLinks -- Click here to rapidly navigate through this document
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the use in this Registration Statement on Form S-1 of Aralez Pharmaceuticals Inc. of our report dated October 29, 2015 relating to the statements of revenue and related expenses related to the rights to Fiorinal, Fiorinal C, Visken and Viskazide Products in Canada of Novartis Pharma AG and Novartis AG, which appears in such Registration Statement. We also consent to the reference to us under the heading "Experts" in such Registration Statement.
PricewaterhouseCoopers AG
| /s/ MARTIN KENNARD Martin Kennard |
/s/ STEVE JOHNSON Steve Johnson |
Basel, Switzerland, December 30, 2015
CONSENT OF INDEPENDENT ACCOUNTANTS